Analysts express confidence in AstraZeneca's 'transformed' pipeline

Despite an initial blip, shares in AstraZeneca (LSE: AZN) have climbed by 8% since the Anglo-Swedish pharma major announced its 2016 results last week, reaching £46.12 ($57.57) by Friday lunchtime.

As always, there was talk of the strength of the company’s pipeline, though in this case it was more than just optimistic rhetoric, according to a pair of healthcare research analysts at the investment bank Cantor Fitzgerald.

"The company has reacted to evolving data generated internally and elsewhere to maximize the potential of MYSTIC to deliver a positive outcome which is more likely to be realized fully in 2018 with the overall survival co-primary endpoint"